Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.400 / 400some concern
inconclusive
  • suggested 24 % decrease in deaths (OS)
  • suggested 39 % decrease in progression or deaths (PFS)

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABCP vs BPC WT), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.356 / 336some concern
conclusif
  • demonstrated 22 % decrease in deaths (OS) (PE)
  • demonstrated 38 % decrease in progression or deaths (PFS) (PE)
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.155 / 129some concern
conclusif
  • demonstrated 49 % decrease in progression or deaths (PFS) (PE)